Lung Cancer

Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

Lack of a statistically significant PFS improvement and improbability of achieving OS benefit led to the discontinuation of the KEYNOTE-D46/EVOKE-03 trial in PD-L1–high NSCLC.

D. Ross Camidge, MD, PhD, reflects on his journey, from a gap year working at McDonald’s to directing the lung cancer program where he is now a patient.

Leah Wells, MD, breaks down the expansion and continued investigation of ADCs in lung cancer management.

First-line asandeutertinib improved intracranial iORR and IPFS vs osimertinib in EGFR-mutated NSCLC with brain metastases.

FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.

The phase 3 HARMONi-6 showed an overall survival benefit with ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in squamous NSCLC.

Adjuvant selpercatinib cut recurrence or death risk by 83% vs placebo in stage IB-IIIA RET fusion–positive NSCLC in LIBRETTO-432.

Seven-year follow-up from the CROWN trial has set a tall benchmark for the agents that followed it on the podium at the 2026 ASCO Annual Meeting in oncogene driven NSCLC.

The phase 3 WU-KONG28 data showed that first-line sunvozertinib improved PFS and ORR vs chemotherapy in EGFR exon 20–mutant NSCLC.

The combination cut the risk of progression or death by 65% in the first phase 3 trial of an ADC plus pembrolizumab in this setting.

Amivantamab plus lazertinib led to a median OS of 41.0 months in EGFR-mutated advanced NSCLC.

At the 2026 ASCO Annual Meeting, results from the 7-year update of the phase 3 CROWN study were presented.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Nicholas Zorko, MD, PhD, discusses B7-H3 targeting in lung, GU, and gynecologic malignancies.

The FDA priority review of neladalkib for TKI-pretreated ALK-positive NSCLC is supported by data from the phase 1/2 ALKOVE-1 trial.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

Sevabertinib has received priority review designation from the FDA in locally advanced or metastatic, HER2 TKD–mutant NSCLC.

OncLive announced the 2026 Giants of Cancer Care winners.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.